Paradromics, headquartered in United States, is publicly traded. Its last mark stands at $500M.
1 valuation. The latest, $500M, was set by the Series B in Feb 2025.
Khosla VenturesParadromics is building a high-data-rate brain-computer interface platform, called Connexus, designed to exchange information between brains and computers. Its first target is restoring communication for people with paralysis from conditions like ALS or spinal cord injury, using an implanted electrode array that reads neural signals at the level of individual neurons.
Founded in 2015 and headquartered in Austin, Texas with a second office in Oakland, California, Paradromics is led by founder and CEO Matt Angle and has begun its first human clinical trial as it works toward FDA approval.
Paradromics trades publicly. A brokerage with access to that exchange can buy the shares.
Index and sector funds may hold Paradromics; a fund's latest schedule of investments lists its holdings.
Valuations, rounds and IPO status for every company in the directory — Paradromics included.
The closest neurotec peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Yes. Paradromics is a publicly traded company.
The last valuation is $500M.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
